Envoy Medical (NASDAQ:COCH) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Envoy Medical (NASDAQ:COCH) posted its quarterly earnings results on Thursday. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.17, FiscalAI reports. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million.

Envoy Medical Stock Performance

Shares of COCH stock traded up $0.05 on Friday, hitting $7.15. 50,474 shares of the stock traded hands, compared to its average volume of 21,609. The firm’s 50-day moving average price is $6.82 and its two-hundred day moving average price is $6.88. The stock has a market capitalization of $55.20 million, a PE ratio of -1.55 and a beta of 2.03. Envoy Medical has a twelve month low of $3.63 and a twelve month high of $9.54.

Analysts Set New Price Targets

A number of analysts have commented on COCH shares. HC Wainwright reiterated a “buy” rating on shares of Envoy Medical in a report on Tuesday, October 13th. Loop Capital set a $20.00 target price on Envoy Medical in a report on Monday, July 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Finally, Lake Street Capital upped their price target on Envoy Medical from $2.50 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $21.67.

About Envoy Medical

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.